CStone Pharmaceuticals, a biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, announced today that the new drug application (NDA) for pralsetinib for the treatment of rearranged during transfection (RET) fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) has been accepted in Hong Kong, China. Pralsetinib is…
eTurboNews tala e mo na'o le au fai saofaga. O le lesitala o saʻoloto.
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE
OA MEA E AVEA MAI LENEI TUSI:
- CStone Pharmaceuticals, o se kamupani biopharmaceutical e taulaʻi i suʻesuʻega, atinaʻe, ma faʻatauga o togafitiga faʻafomaʻi immuno-oncology ma vailaʻau saʻo, faʻasalalau i aso nei o le faʻaaogaina o fualaau faasaina (NDA) mo le praksetinib mo le togafitiga o le toe faʻatulagaina i le taimi o le transfection (RET) fusion-positive i le lotoifale. Ua talia i Hong Kong, Saina le kanesa o le mama sela e le o ni metastatic (NSCLC).
- O le lesitala e leai se totogi.
- eTurboNews tala e mo na'o le au fai saofaga.
